(Use several sheets if necessary)

10/634,047
August 4, 2003
Roland MAIER
1624
Mark L. BERCH
01-1385

				U.:	S, PATENTS	
Examiner Initial*	Cite No.	Patent Number	Kind Code	Issue Date yyyy/mm/dd	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments
	1.	2928833		1960-03-15	Leake et al	
	2.	4005208		1977-01-25	Bender	
	3.	4599338		1986-07-08	Regnier et al.	This patent appears to be an English language equivalent toEP0149578 cited herein.
	4.	5051517		1991-09-24	Findeisen	This patent appears to be an English language equivalent toEP0399285 cited herein.
	5.	5223499	A	1993-06-29	Greenlee	
	6.	5234897	A	1993-08-10	Findeisen et al.	
	7.	5266555	А	1993-11-30	Findeisen et al.	This patent appears to be an English language equivalent toEP0524482 cited herein.
	8.	5389642	A	1995-02-14	Dorsch	
	9.	5470579	A	1995-11-28	Bonte et al.	This patent appears to be an English language equivalent toWO9107945 cited herein.
	10.	5719279	A	1998-02-17	Kuefner-Muhl et al.	This patent appears to be an English language equivalent toWO94/03456 cited herein.
	11.	5753635	А	1998-05-19	Buckman	
	12.	6303661	B1	2001-10-16	Demuth	
	13.	6342601	B1	2002-01-29	Bantick	
	14.	6548481	B1	2003-04-15	Demuth et al.	
	15.	6821978	B2	2004-11-23	Chackalamannil	
	16.	6869947	B2	2005-03-22	Kanstrup	
	17.	7060722	B2	2006-06-13	Kitajima	
	18.	7074794	B2	2006-07-11	Kitajima	This patent appears to be an English language equivalent toWO2002/14271 cited herein.
	19.	7074798	B2	2006-07-11	Yoshikawa	
	20.	7074923	B2	2006-07-11	Dahanukar	
	21.	7109192	B2	2006-09-19	Hauel	
	22.	7179809	B2	2007-02-20	Eckhardt	
	23.	7183280	B2	2007-02-27	Himmelsbach	
	24.	7192952	B2	2007-03-20	Kanstrup	
		7217711	B2	2007-05-15	Eckhardt	
	26.	7235538	B2	2007-06-26	Kanstrup et al.	

	U.S. PATENT APPLICATION PUBLICATIONS					
Examiner Initial*	Cite No.				of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments
	1.	11/744700		2007-05-04	Sieger	
	2.	11/744701		2007-05-04	Kohlrausch	

Examiner:	Date Considered:
-----------	------------------

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

Application Number:	10/634,047
Filing Date:	August 4, 2003
First Named Inventor:	Roland MAIER
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1385

	_		U.S. I	PATENT APPLIC	CATION PUBLICATIONS	Pages, Columns, Lines where Relevant
Examiner Initial*	Cite No.	Publication Number	Kind Code	Publication Date yyyy/mm/dd	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear of Relevant Comments
	3.	2002/0161001	A1	2002-10-31	Kanstrup	ice vant Comments
	4.	2002/0169174	A1	2002-11-14	Chackalamannil et al.	
						This document appears to be an apparent English language equivalent to
	5.	2002/0198205	A1	2002-12-26	Himmelsbach	WO2002068420 cited herein.
	6.	2003/0199528	A1	2003-10-23	Kanstrup	
	7.	2003/0232987	A1	2003-12-18	Dahanukar et al.	
	8.	2003/0236272	A1	2003-12-25	Carr	
	9.	2003/0105077	A1	2003-06-05	Kanstrup, A.B. et al.	
	10.	2004/0034014	A1	2004-02-19	Kanstrup, A.B. et al.	
	11.	2004/0077645	A1	2004-04-22	Himmelsbach et al.	This document appears to be an apparent English language equivalent to WO2002068420 cited herein.
	12.	2004/0082570	A1	2004-04-29	Yoshikawa	
	13.	2004/0087587	A1	2004-05-06	Himmelsbach	
	14.	2004/0097510	A1	2004-05-20	Himmelsbach et al.	
	15.	2004/0122228	A1	2004-06-24	Maier	
	16.	2004/0138214	A1	2004-07-15	Himmelsbach et al.	
	17.	2004/0138215	A1	2004-07-15	Eckhardt	This document appears to be an apparent English language equivalent to WO2004/046148 cited herein.
	18.	2004/0166125	A1	2004-08-26	Himmelsbach	
	19.	2005/0020574	A1	2005-01-27	Hauel, N. et al.	
	20.	2005/0026921	A1	2005-01-27	Eckhardt	
	21.					
	21.	2005/0130985	A1	2005-06-16	Himmelsbach	
	22.	2005/0171093	A1	2005-08-04	Eckhardt et al.	
	23.	2005/0187227	A1	2005-08-25	Himmelsbach et al.	
	24.	2005/0203095	A1	2005-09-15	Eckhardt	
	25.	2005/0234108	A1	2005-10-20	Himmelsbach et al.	
	26.	2005/0261352	A1	2005-11-24	Eckhardt	
	27.	2006/0004074	A1	2006-01-05	Eckhardt	
	28.	2006/0058323	A1	2006-03-16	Eckhardt et al.	
	29.	2006/0063787	A1	2006-03-23	Yoshikawa	
	30.					This document appears to be an apparent English language equivalent to
	30.	2006/0079541	A1	2006-04-13	Langkopf	WO2006/029769 cited herein. This document appears to be an apparent
	31.	2006/0142310	A1	2006-06-29	Pfrengle et al.	English language equivalent to WO2006/048427 cited herein.
	32.	2006/0173056	A1	2006-08-03	Kitajima	
	33.	2006/0205711	A1	2006-09-14	Himmelsbach	This document appears to be an apparent English language equivalent to DE10117803 cited herein.

	33.	2006/0205711	A1	2006-09-14	Himmelsbach	DE10117803 cited herein.
Examine	r:			п	Date Considered:	

(Use several sheets if necessary)

Application Number:	10/634,047
Filing Date:	August 4, 2003
First Named Inventor:	Roland MAIER
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1385

	U.S. PATENT APPLICATION PUBLICATIONS							
Examiner Initial*	Cite No.	Publication Number			Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments		
	34.	2006/0247226	A1	2006-11-02	Himmelsbach			
	35.	2007/0027168	A1	2007-02-01	Pfrengle et al.			
	36.	2007/0088038	A1	2007-04-19	Eckhardt			
	37.	2007/0093659	A1	2007-04-26	Bonfanti			
	38.	2007/0142383	A1	2007-06-21	Eckhardt			
	39.	2007/0281940	A1	2007-12-06	Dugi			

	FOREIGN PATENT DOCUMENTS							
Examiner		Foreign Document	Country	Kind	Publication	Name of Patentee or Applicant of	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant	J.
Initial*	No.	Number	Code	Code	Date	cited Document	Comments	$\sqrt{1}$
	1.	2136288	CA	A1	1995-05-24	Merck Patent GmbH	This document appears to be an apparent English language equivalent to EP0657454 cited herein	
	2.	2418656	CA	A1	2002-02-21	Mitsubishi Pharma Corporation		
	3.	2496249		A1	2004-04-03	BI Pharma GmbH &	This document appears to be an apparent English language equivalent to WO2004018468 cited herein	
	4.	2496325	CA	A1	2004-03-04	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO20040184687 cited herein	
	5.	2505389	CA	A1	2004-05-21	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO2004041820 cited herein	
	6.	2508233	CA	A1	2004-06-17	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO2004050658 cited herein	
	7.	2529729	CA	A1	2004-12-23	BI International GmbH	This document appears to be an apparent English language equivalent to WO2004111051 cited herein	
	8.	2543074	CA	A1	2005-06-30	BI International GmbH	This document appears to be an apparent English language equivalent to WO2005/058901 cited herein	
	9.	2555050	CA	A1	2005-09-15	BI International GmbH	This document appears to be an apparent English language equivalent to WO2005/085246 cited herein	
	10.	2556064	CA	A1	2005-09-09	BI International GmbH	This document appears to be an apparent English language equivalent to WO2005/082906 cited herein	
	11.	2590912	CA	A1	2006-06-29	Dainippon Sumitomo Pharma Co., Ltd.	This document appears to be an English language equivalent to WO2006068163 cited herein	

 $^{^{1}}$ $\sqrt{\text{indicates English Language translation is attached}}$

Examiner:	Date Considered:			
*Examiner: Initial if citation considered, whether or not ci	itation is in conformance with MPEP Section 609; Draw line through			
citation if not in conformance and not considered. Include a	yony of this form with next communication to applicant	ı		

INFORMATION DISCLOSURE STATEMENT BY APPLICATION

(Not for submission under 37 CFR 1.99) (Use several sheets if necessary)

Application Number:	10/634,047
Filing Date:	August 4, 2003
First Named Inventor:	Roland MAIER
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1385

			FOREIG	N PATENT I	OCUMENTS		
12.	10109021	DE.	A1	2002-09-05	Boehringer Ingelheim Pharma KG	US2006/0205711 cited herein appears to be an apparent English language equivalent	
	10109021	DE		2002-09-05	Boehringer Ingelheim	equivalent	1
13.	10117803	DE	A1	2002-10-24	Pharma KG		
14.	0149578	EP	A2	1985-07-24	ADIR	US4599338 cited herein appears to be an apparent English language equivalent	
15.	0399285	ED.	A1	1990-11-28	Royar A.C.	US5051517 cited herein appears to be an apparent English language equivalent	
16.	0400974		A2		Merck & Co. Inc.	equivalent	
17.							1/
17.	0412358	EP	A1	1991-02-13	Bayer AG	US5266555 cited herein appears to be	· ·
18.	0524482	EP	A1	1993-01-27	Bayer AG	an apparent English language equivalent	
19.	0657454	E0	A1	1005.06.14	Merck Patent GmbH	CA2136288 cited herein appears to be an apparent English language equivalent	
20.	1338595		A1 A2	2003-08-27		oquivaio/it	
21.	1514552		A1		Eisai Co. Ltd		
22.	1537880		A1		Takeda Pharmaceutical Company Limited		
23.	385302	ES	A1		Laboratorios Miquel		V
24.	2707641		A1		Fournier Ind. Et Sante		<u> </u>
25.	2003/300977			2003-10-21	Sumitomo Pharma		√
26.	2006/045156	JP		2006-02-16	Sumitomo Pharma		V
27.	\$37-4895	In.		4000.00.40	Yoshitomi Pharmaceutical Corp.		√
28.	91/07945		A1		LVMH Recherche	US5470579 cited herein appears to be an apparent English language equivalent	,
29.	94/03456	wo	A1	1994-02-17	Boehringer Ingelheim Int'l GmbH	US5719279 cited herein appears to be an apparent English language equivalent	
30.	99/29695	wo	A1	6/17/1999	Astra Aktiebolag		
31.	2002/02560	wo	A2	2002-01-10			
32.	2002/068420	wo	A1	2002-09-06	Boehringer Ingelheim Pharma KG	US2002/198205 cited herein appears to be an apparent English language equivalent	
33.	2002/14271	wo	A1	2002-02-21	Welfide Corporation	US7074794 cited herein appears to be an apparent English language equivalent	
34.	2002/24698		A1	-	Schering Corporation	- Squirtaioni	-
35.	2002/24698		A1		Novo Nordisk A/S		-
36.	2003/024965		A2	2003-01-10			
37.	2003/057200		A2	2003-03-27			_
38.	2003/104229		A1		Eisai Co., Ltd.	US2004116328 cited herein appears to be an apparent English language equivalent	

Examiner:	Date Considered:
#Evancinas Initial if sitution considered vehathor or not si	totion is in conformance with MDED Castion 600: Draw line through

(Use several sheets if necessary)

Application Number:	10/634,047
Filing Date:	August 4, 2003
First Named Inventor:	Roland MAIER
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1385

			FOREIG	N PATENT I	OCUMENTS		
					Boehringer Ingelheim	CA2496325 cited herein appears to be	Ι_
					Pharma GmbH & Co.	an apparent English language	
39.	2004/018467	wo	A2	2004-03-04	KG	equivalent	
					Boehringer Ingelheim	CA2496249 cited herein appears to be	Т
					Pharma GmbH & Co.	an apparent English language	
40.	2004/018468	wo	A2	2004-03-04	kg	equivalent	
41.	2004/033455		A2	2004-04-22	Novo Nordisk		Т
						CA2505389 cited herein appears to be	†
					Boehringer Ingelheim	an apparent English language	
42.	2004/041820	wo	A1	2004-05-21	Pharma GmbH	equivalent	П
	EGO NO TIOEO		7.11	20010021	Boehringer Ingelheim	US2004/0138215 cited herein appears	t
					Pharma GmbH & Co.	to be an apparent English language	1
43.	2004/046148	wo	A1	2004-06-03		equivalent	
1.51			- 1.11		Sumitomo Pharm		t
44.	2004/048379	wo.	A1	2004-06-10			l۷
	20041040010	""	- /**	2004-00-10	Boehringer Ingelheim	CA2508233 cited herein appears to be	۲
					Pharma GmbH & Co.	an apparent English language	
45.	2004/050658	wo.	A1	2005-06-17		equivalent	ı
15.	2004/00000	1110		2000-00-17	Fujisawa Pharma.	oquivaioix	۰
46.	2004/108730	wo	A1	2004-12-16			
10.	2004/100/30	1110		2004-12-10	CO., Eld.	CA2529729 cited herein appears to be	۰
						an apparent English language	
47.	2004/111051	wo	A1	2005 12 22	BI Int'l GmbH	equivalent	
	2004/111001	****	- 171	2000-12-20	DI IIICI GIIIDII	CA2543074 cited herein appears to be	+
						an apparent English language	
48.	2005/058901	wo	A1	2005 06 20	Bi Int'i GmbH	equivalent	
70.	2000/000901	WO	- 1	2003-00-30	BI IIILI GIIIDH	CA2556064 cited herein appears to be	⊢
						an apparent English language	
49.	2005/082906	WO.	A1	2005 00 00	BI Int'l GmbH	equivalent	П
49.	2000/002900	1110	-141	2003-09-09	DI IIICI GIIIDA	CA2555050 cited herein appears to be	+
1 1				1		an apparent English language	
50.	2005/085246	lwo	A1	2005.00.45	DU-M C		
30.	2005/085246	WO	A1	2005-09-15	BI Int'l GmbH	equivalent US2006079541 cited herein appears	۰
					BI Pharma GmbH &		
51.	000000000000	lwo	A1	1 0000 00 00		to be an apparent English language	
31.	2006/029769	WU	A1	2006-03-23	CO. NG	equivalent	₽
1 1						US2006142310 cited herein appears	
52.	0000001010107			0000000	la	to be an apparent English language	
52.	2006/048427	WO	A1	2006-05-11	BI Int'l GmbH	equivalent	₽
62		l	1	1	Dainippon Sumitomo	CA2590912 cited herein appears to be	
53.	2006/068163	wo	A1	2006-06-29	Pharma Co., Ltd.	an English language equivalent	L
1			1		F. Hoffmann-La		
54.	2007/017423	IWO	A2	2007-02-15	IRoche AG	I	1

NON-PATENT LITERATURE DOCUMENTS									
Examiner Initial*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the liter (look, magazine, journal, serial, symposium, catalog, etc), date, pages (s), volume-issue number(s), publisher, city and/or country where published.	$\sqrt{2}$						
	1.	BELJEAN-LEYMARIE et al., Hydrazines et hydrazones hétérocycliques. IV. Synthèses de dérivés de l'hydrazine dans la série des imidazo[4,5-d]pyridazinones-4, Can. J. Chem., Vol. 61, No. 11, 1983, pp. 2563-2566.	√						
	2.	BOLLAG, R.J. ET AL; "Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors," Endocrinology, Vol. 141, No. 3, 2000, pp. 1228-1235.							

 $^{^2~\}sqrt{}$ indicates English Language translation is attached

Examiner:	Date Considered:	
	itation is in conformance with MPEP Section 609; Draw line through	
citation if not in conformance and not considered. Include of	copy of this form with next communication to applicant.	

(Use several sheets if necessary)

10/634.047
August 4, 2003
Roland MAIER
1624
Mark L. BERCH
01-1385

3.	BRITTAIN, H.G., "Methods for the Characterization of Polymorphs: X-Ray Powder Diffraction," Polymorphism in Pharmaceutical Solids, 1999, p. 235-238	
4.	CAIRA, M.R., "Crystalline polymorphism of organic compounds" Topics in Current Chemistry, Springer, Berlin, Vol. 198, 1998, p. 163-208	
5.	CONARELLO, S.L. ET AL: "Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance," PNAS 2003; 100:6825-6830, originally published online May 14, 2003; information current as of December 2006. www.pnas.org/cgi/content/full/100/11/6825.	
6.	DEACON, C.F. ET AL; "Dipeptidyl peptidase IV inhabitation as an approach to the treatment and prevention of type 2 diabetes: a historical perspective;" Biochemical and Biophysical Research Communications (BBRC) 294 (2002) 1-4.	
7.	DeMEESTER, I. ET AL.; "CD26, let it cut or cut it down", Review: Immunology Today; August 1999, Vol. 20, No. 8 pp.367-375	
8.	KOROM, S. ET AL; "Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients ¹² , Transplantation, May 27, 1997, Vol. 63, no 10, pp 1495-1500.	
9.	POSPISILIK, ET AL; "Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β -Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats; Diabetes, Vol. 52, March 2003 pp 741-750.	
10.	RHEE ET AL.: "Nitrogen-15-Labeled Deoxynucleosides, 3. Synthesis of [3-15N]-2-Deoxyadenosine" J. Am. Chem. Soc. 1990, 112, 8174-8175	
11.	SEDO, A. ET AL; "Dipeptidyl peptidase IV activity and/or structure homologs: Contributing factors in the pathogenesis of rheumatoid arthritis?" Arthritis Research & Therapy 2005, Vol. 7, pp. 253-269	
12.	TANAKA, S., ET AL; "Suppression of Arthritis by the Inhibitors of Dipeptidyl Peptidase IV," In. J. Immunopharmac., Vol. 19, No. 1, pp. 15-24, 1997	
	WOLFF, M.E.: "Burger's Medicinal Chemistry and Drug Discovery" Fifth Edition, Vol 1: Principles and Practice, pgs. 975-977, 1994, John Wiley & Sons, Inc.,	
	ZHONG, QING ET AL; "Glucose-dependent insulinotropic peptide stimulates proliferation and TGF-β release from MG- 63 cells," Peptides 24 (2003) 611-616	
	Chemical Abstracts Accession No. 1987:95577: Abstract of ROMANENKO et al., "Synthesis and biological activity of 3-methyl, 7-or 8-alkyl, 7-8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," Farmatsevtichnii Zhurnal, 1986, (Kiev), Vol. 5, 1986, pp. 41-44.	
	Chemical Abstracts Accession No. 106:95577 ROMANENKO ET AL., "Synthesis and biological activity of 3-methyl, 7-or 8-alkyl-7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," Zaporozh. Med. Institute (1986)	
17.	YOSHIKAWA, SEIJI ET AL.: Chemical Abstract of Japanese Patent No. WO 2003/104229 *Preparation of purinone derivatives as dipeptidylpeptidase IV (DPP-IV) inhibitors	
18.	International Search Report for PCT/EP03/09127 mailed November 28, 2003.	
19.	International Search Report for PCT/EP03/12821 mailed March 30, 2004.	
20.	International Search Report for PCT/EP03/13648 mailed April 5, 2004.	
21.	International Search Report for PCT/EP2007/054270 mailed August 14, 2007.	
22.	International Search Report for PCT/EP2007/058181 mailed November 28, 2007.	
23.	International Search Report for PCT/EP2007/054204 mailed August 3, 2007.	
24.	International Search Report for PCT/EP2007/054201 mailed August 29, 2007	

Examiner:					Date Considered:								
4.70	* 1:1 1 10 1: · · ·							1.4.3.49999		m			-